IRIS
PIERANTOZZI, MARIANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 52.366
AS - Asia 9.835
EU - Europa 8.992
Continente sconosciuto - Info sul continente non disponibili 943
SA - Sud America 915
AF - Africa 90
OC - Oceania 16
Totale 73.157
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 52.090
SG - Singapore 6.534
IT - Italia 4.361
CN - Cina 1.084
RU - Federazione Russa 770
BR - Brasile 764
DE - Germania 677
UA - Ucraina 642
HK - Hong Kong 624
IE - Irlanda 512
FR - Francia 506
VN - Vietnam 471
BD - Bangladesh 390
NL - Olanda 357
GB - Regno Unito 322
SE - Svezia 203
FI - Finlandia 187
JP - Giappone 171
PL - Polonia 159
CA - Canada 148
KR - Corea 144
IN - India 95
AR - Argentina 62
ID - Indonesia 59
MX - Messico 49
TR - Turchia 47
IQ - Iraq 43
AT - Austria 41
ZA - Sudafrica 37
BE - Belgio 36
CH - Svizzera 34
ES - Italia 31
JM - Giamaica 24
EU - Europa 21
GR - Grecia 21
CZ - Repubblica Ceca 20
EC - Ecuador 20
PK - Pakistan 20
RO - Romania 17
UZ - Uzbekistan 16
VE - Venezuela 16
MY - Malesia 15
SA - Arabia Saudita 15
AL - Albania 14
CO - Colombia 14
MA - Marocco 14
AE - Emirati Arabi Uniti 13
AU - Australia 13
PY - Paraguay 13
CR - Costa Rica 12
AZ - Azerbaigian 11
CL - Cile 11
LT - Lituania 11
IL - Israele 10
DK - Danimarca 9
EG - Egitto 9
HR - Croazia 9
KG - Kirghizistan 9
NP - Nepal 9
TT - Trinidad e Tobago 9
PH - Filippine 8
KE - Kenya 7
PE - Perù 7
PT - Portogallo 7
SM - San Marino 7
TN - Tunisia 7
TW - Taiwan 7
BO - Bolivia 6
KZ - Kazakistan 6
NI - Nicaragua 6
SK - Slovacchia (Repubblica Slovacca) 6
IR - Iran 5
LB - Libano 5
RS - Serbia 5
BG - Bulgaria 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
JO - Giordania 4
MD - Moldavia 4
SI - Slovenia 4
TH - Thailandia 4
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
AM - Armenia 2
AO - Angola 2
DM - Dominica 2
DZ - Algeria 2
GT - Guatemala 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PR - Porto Rico 2
QA - Qatar 2
SN - Senegal 2
Totale 72.207
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.667
Wilmington 13.040
Houston 11.891
Fairfield 1.735
Singapore 1.572
Ashburn 1.188
Ann Arbor 1.069
San Jose 797
Hong Kong 617
Seattle 611
Cambridge 594
Chandler 593
Rome 592
Jacksonville 575
Dublin 473
Council Bluffs 426
Beijing 404
Milan 393
Medford 358
Los Angeles 311
Santa Clara 295
New York 270
The Dalles 259
Dearborn 231
Lawrence 167
Tokyo 151
Lauterbourg 146
Ho Chi Minh City 141
Buffalo 136
Hanoi 124
Moscow 116
Kraków 111
San Diego 97
Naples 95
Florence 83
Dallas 82
London 75
Munich 72
Menlo Park 69
Turin 68
São Paulo 67
Bologna 65
Chicago 58
Verona 57
North Bergen 56
Helsinki 52
Phoenix 47
Brooklyn 45
Toronto 44
Nuremberg 42
Genoa 41
Shanghai 41
Norwalk 38
Orem 37
Warsaw 37
Durham 36
Mülheim 36
Zhengzhou 36
Montreal 35
Atlanta 34
Falls Church 33
Jakarta 33
Redondo Beach 33
Boardman 32
Brussels 32
Redwood City 32
Chennai 31
Bari 27
Johannesburg 27
Stockholm 27
Catania 26
Padova 26
Amsterdam 25
Boston 25
Denver 24
Mountain View 24
Frankfurt am Main 23
Manchester 23
Modena 23
Philadelphia 23
Rio de Janeiro 23
Miami 22
Nanjing 22
Palo Alto 22
Sassari 22
Trento 22
Seoul 21
St Louis 21
Mexico City 19
Salt Lake City 19
University Park 19
Belo Horizonte 18
Bolzano 18
Da Nang 18
Hefei 18
Palermo 18
Reggio Emilia 18
Kunming 17
Shenzhen 17
Brasília 16
Totale 55.537
Salva come PNG Salva come JPEG
Nome #
Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT) 3.366
malattia di alzheimer e altre demenze diagnosi e terapia integrata. 834
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 639
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 621
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease 614
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 610
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 606
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 604
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 599
Therapy for dyskinesias in Parkinson’s disease patients 598
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 593
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 576
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 573
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 570
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 561
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 553
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 547
Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic study 537
Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease 536
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 527
123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study 519
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 512
Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease 508
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 508
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 501
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 497
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 496
Adherence to anti-Parkinson drug therapy in the "rEASON" sample of Italian patients with Parkinson's disease: The linguistic validation of the Italian version of the "morisky Medical Adherence scale-8 items" 496
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 495
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients 495
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 492
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus. 488
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 487
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 487
Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study 485
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 483
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 481
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 481
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 476
Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes 476
SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status 473
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 473
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 473
The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease 470
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 469
Electrophysiological evidence for visuocognitive dysfunction in younger non Caucasian patients with Parkinson's disease 467
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 460
123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms 460
Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease 459
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 457
Optic Nerve dysfunction in obstructive sleep apnea: An electrophysiological study 452
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 451
Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: An effective tool to investigate in vivo GABAergic cortical inhibition in humans 449
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 448
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 448
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations 446
Age and stage dependency of P300 latency alterations in non-demented Parkinson's disease patients without therapy 444
Restless legs syndrome and poliomyelitis: New evidences of an old observation? 444
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 443
Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity 443
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 443
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients 441
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 441
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study 440
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 438
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome 438
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 437
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease 437
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 436
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 436
Alexithymia is a non-motor symptom of Parkinson disease 433
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 431
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study 430
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 428
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients 427
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients - An ambulatory polysomnographic study 426
Emotional processing in Parkinson's disease. A study using functional transcranial doppler sonography 421
Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials 420
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 419
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 418
Catecholamine-based treatment in AD patients: expectations and delusions 415
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 413
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 412
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 409
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 409
Restless legs syndrome and post polio syndrome: a case-control study 405
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss? 404
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 402
Neurological complications of pregnancy 402
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 401
Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients 398
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 396
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study 395
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 394
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 393
P3 components evoked by unilateral and bilateral somatosensory stimulation: normative data for the study of neglect syndrome 389
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease 388
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 388
Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study 387
When cognitive decline and depression coexist in the elderly: CSF biomarkers analysis can differentiate Alzheimer's disease from late-life depression 386
Totale 50.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 169.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 169.179
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.908 0 246 96 74 67 130 316 88 114 132 146 499
2022/20231.905 209 129 69 209 138 455 176 97 149 36 145 93
2023/20241.698 123 56 109 104 149 199 147 256 69 132 104 250
2024/20259.692 218 1.116 601 455 249 444 437 388 571 553 2.637 2.023
2025/20269.551 716 327 995 795 797 308 1.160 1.213 969 978 749 544
2026/20271.356 818 538 0 0 0 0 0 0 0 0 0 0
Totale 73.157